Loading
A phase 3 trial of Flumatinib in Leukaemia, run by Zhongda Hospital, with a status the registry has not verified recently.
Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL is a phase 3 interventional study registered as NCT04375683 by Zhongda Hospital, with 28 participants planned, started 2020-03-01 and due to reach its primary completion in 2022-12-30. Interventions recorded: Flumatinib. Conditions recorded: Acute Lymphocytic Leukemia, Adult B-Cell, BCR-ABL1 Fusion Protein Expression.
Linked to the drug Flumatinib because the registry names it among its interventions and Leukaemia among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Flumatinib, Leukaemia (all types) and the tag pipeline.
Shares Flumatinib, Leukaemia (all types) and the tag pipeline.
Shares Leukaemia (all types) and the tag pipeline.
Shares Leukaemia (all types) and the tag pipeline.
Shares Leukaemia (all types) and the tag pipeline.
Shares Leukaemia (all types) and the tag pipeline.
Shares Leukaemia (all types) and the tag pipeline.
Shares Leukaemia (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/